| Advances in Breast Cancer Therapy |
Jun 2010 |
12 pages |
| Authors:
Holly Gallion; PRECISION THERAPEUTICS INC PITTSBURGH PA
|
 | A total of 39 specimens have been submitted to Precision for this study. Twenty (20) subjects have been enrolled in this study to date. Tissue was submitted at the time of a diagnostic core biopsy procedure for nineteen (19) subjects. Seventeen (17) subjects' results did not qualify them for the main research study. Two (2) subjects' pathology reports and enrollment on the study is pending. One (1) subject was discontinued ... |
|
| Advances in Breast Cancer Therapy |
Jun-2009 |
10 pages |
| Authors:
Holly Gallion; PRECISION THERAPEUTICS INC PITTSBURGH PA
|
| PTI has received WIRB approval and the University of Pittsburgh IRB approval for this study. PTI has engaged 19 research sites in this research and four contracts have been successfully negotiated and executed. Another six research sites are determining clinical and budgetary feasibility. Pending the approval of the DoD and the WIRB of this first set of research sites submitted for approval, it is anticipated we will have the first ... |
|
| Advances in Breast Cancer Therapy (IBRP) |
01-May-2008 |
5 pages |
| Authors:
Holly Gallion; PRECISION THERAPEUTICS INC PITTSBURGH PA
|
| Therapeutics, Inc. 1) wrote and gained approval for the data safety monitoring plan for this protocol; 2) identified and contracted a medical monitor for this protocol; 3) revised the protocol, informed consent and case report forms, and obtained approval by the USAMRMC ORP HRPO; 4) submitted the protocol and informed consent form to the Western IRB for approval; 5) is collaborating with Windber Research Institute in the preparation of the ... |
|
Reports by Author
